FDA Pulls Back on Stricter Rules for Tanning Beds and Sunlamps
Published Date: 3/16/2026
Proposed Rule
Summary
The FDA has decided to stop moving forward with a 2015 plan that would have put stricter rules on selling and using sunlamp products like tanning beds. This means businesses and users won’t face new restrictions or extra costs from this rule. The withdrawal is official as of March 16, 2026, so things stay as they are for now.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Existing 2014 Sunlamp Rules Still Apply
Sunlamp products were reclassified to class II in a June 2, 2014 order that became effective September 2, 2014, making them subject to 510(k) premarket notification and special controls. Those special controls include performance testing, labeling requirements, and a warning that sunlamp products should not be used on persons under age 18.
Proposed Sunlamp Restrictions Withdrawn
The FDA withdrew its December 22, 2015 proposed rule on restricting sale, distribution, and use of sunlamp products. As of March 16, 2026, businesses and users will not face the new restrictions or extra costs that would have come from that proposed rule, so current practices remain in place for now.
Performance Standard Amendments Unaffected
FDA said its proposed amendments to the sunlamp products and UV lamps performance standard at 21 CFR 1040.20 are not affected by this withdrawal. That means the separate proposed technical and labeling updates at 21 CFR 1040.20 remain a separate action.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-05097 — Amendment of Class D and Class E Airspace and Revoke Class E Airspace; Fort Knox, KY
The FAA is updating the airspace rules around Fort Knox, KY, because an old navigation beacon was turned off. This means changing some flight zones and removing others to keep things safe and clear for pilots. If you fly or work near Fort Knox, these changes could affect you starting soon, and the FAA wants your feedback by April 30, 2026.
Next: 2026-05105 — Prediction Markets
The Commodity Futures Trading Commission (CFTC) is asking for your thoughts on prediction markets—places where people bet on future events. They want to know what rules should apply, which bets might be off-limits, and how these markets impact everyone. If you have ideas, send them by April 30, 2026, because this could lead to new rules that affect traders and the public.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in